FDA Approves ZURZUVAEā„¢ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

Go back to FDA Approves ZURZUVAEā„¢ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 250.69 -3.15 (1.24%)
Previous Close $253.84    52 Week High $333.65 
Open $251.68    52 Week Low $223.02 
Day High $252.44    P/E 32.10 
Day Low $246.15    EPS $7.81 
Volume 1,157,377       

Sagebrush Gold Ltd. (NASDAQ: SAGE) Delayed: 8.68 --0 (-0%)
Previous Close $8.68    52 Week High $62.64 
Open $8.68    52 Week Low $26.28 
Day High $8.68    P/E N/A 
Day Low $8.68    EPS $-0.94 
Volume 288,371